REVIEW ARTICLE JPAR 2023

Journal of Pharmaceutical Advanced Research

(An International Multidisciplinary Peer Review Open Access monthly Journal)

Available online at: www.jparonline.com

The Role of Biomarkers in the Field of Pharmaceuticals

Babita Sahu[1], Bhisham Sahu[1], Jharna Sahu[1], Deepak Kumar[1], Suchita Wamankar[2]*, Rajesh Kumar Nema[2]

[1]Rungta Institute of Pharmaceutical Sciences and Research, Kohka, Bhilai, Durg, Chhattisgarh-490024, India.
[2]Rungta Institute of Pharmaceutical Sciences, Bhilai, Durg, Chhattisgarh-490024, India.

Received: 05.10.2023 Revised: 04.11.2023 Accepted: 14.11.2023 Published: 30.11.2023

ABSTRACT: In the pharmaceutical sector, biomarkers have become priceless tools that help with the creation and improvement of innovative therapeutics. This study examines the various ways that biomarkers are used in drug development, clinical research, and personalized medicine. Biomarkers are quantifiable indications of biological processes, disease states, or therapy responses that offer vital information about the effectiveness, safety, and patient stratification of treatments. This paper presents an overview of various types of biomarkers, including genetic, protein, imaging, and pharmacodynamic biomarkers, and discusses their applications in different stages of pharmaceutical research and development. Additionally, the challenges and opportunities associated with biomarker identification, validation, and implementation are explored. The success rate of clinical trials has been greatly increased because of the incorporation of biomarkers in drug development pipelines. Precision medicine methods have also been made easier, and the transition of effective therapies from the lab to the clinic has been sped up. The development of liquid biopsies and the use of artificial intelligence and machine learning algorithms for biomarker identification are two more rising trends and future possibilities in biomarker research that are discussed. Overall, this review highlights how crucial biomarkers are to the progress of pharmaceutical science and how they have the power to completely change patient care by making it possible to create more individualized and effective therapeutic interventions.

Corresponding author:
Ms. Suchita Wamankar
Associate Professor
Rungta Institute of Pharmaceutical Sciences,
Bhilai, Durg, Chhattisgarh-490024, India.
Tel: +91-9893477847
E. Mail ID: suchitawamankar@gmail.com

Keywords: Biomarkers, Drug Discovery, Artificial Intelligence, Machine learning, Research, Development.

INTRODUCTION:

To designate a molecular alteration in a biological molecule that results from assault by reactive oxygen, nitrogen, or halide species, the term "Biomarkers" has been adopted from molecular epidemiology by free radicals [1]. The use of biomarkers in the treatment and diagnosis of the cardiovascular disease, cancer, immune system disorders, and infections is all common [2].

The use and development of tools and technologies, the detection of drug discovery and development, and the understanding of prediction, causes, development, reversion, consequence, diagnosis, and treatment of disease are all included under the broad term "Biomarkers" [3]. Biomarkers may be helpful at many points along the illness cycle [4]. They can be helpful for the actual substance of primary prevention, which is illness prevention. They can also aid in secondary prevention through early disease interruption through screening, sub-acute illness identification, and additional disease growth monitoring [5]. Additionally, biomarkers are helpful for tertiary prevention and assisting in directing treatment to prevent illness brought on by stable disease [6]. Biomarkers, if these occur and have received sufficient validation. In biomedical research and development,[1-7] can be extremely important, including: Using them to establish the presence of an illness through diagnostics Stratification of illness severity and disease growth prediction Calculating and forecasting any clinical benefits or toxicities brought about by a medicinal intervention Keeping track of treatment outcomes, including target involvement when necessary, biomarkers can be utilized as part of a personalized medicine model to tailor treatment to a patient's unique disease features [7]. Additionally, they can be utilized to better comprehend disease mechanisms and locate new disease targets [8].



Fig 1. Types of Biomarkers.

Broadly speaking, biomarkers include molecular entities, images, or other measured activities or properties, or their combination as a biomarker group. They are, ideally, quantitatively measured indicators of biological or pathophysiological processes or the response to therapeutic intervention [9]. They consist of proteins, protein changes, or protein-related processes, like enzymes [10]. Single Nucleotide Polymorphisms (SNPs), Gene Copy Number Variations (CNVs), DNA insertions, deletions, rearrangements such as inversions and translocations larger than 1 kb and deletions less than 1 kb, and mRNA, or long non-coding RNA, are examples of DNA-based biomarkers. Circulating DNA, for example, can be used to diagnose genetic diseases such as Down's syndrome in unborn children [11].

TYPES OF BIOMARKERS:

Based on their distinct roles and properties, biomarkers can be divided into many kinds:

Diagnostic Biomarkers:

Diagnostic biomarkers are utilized by healthcare professionals to determine the presence or absence of specific diseases or medical conditions, valuable indicators aid in the early detection and prompt intervention for patients with a particular ailment [12].

For example, Prostate cancer is diagnosed by measuring prostate-specific antigen (PSA) levels in blood. Elevated PSA levels may suggest the presence of cancer, enabling early detection and prompt intervention [13]. However, it is important to note that other factors such as benign prostatic hyperplasia or inflammation can also cause raised PSA levels. Confirming the presence of cancer usually requires additional tests, such as a biopsy. While PSA has limitations as a diagnostic biomarker, it remains an invaluable tool for screening and monitoring prostate cancer.

Prognostic Biomarkers:

Prognostic biomarkers offer valuable insights into the probable outcome and progression of a disease in an individual [14]. They assist healthcare professionals in gauging the trajectory of the disease and anticipating the overall prognosis for their patients.

Circulating tumor cells (CTCs) are an important prognostic biomarker in cancer patients. CTCs are cancer cells that have separated from the main tumor and are circulating in the bloodstream. They contain important information about the aggressiveness of the tumor, the likelihood of metastasis, and the patient's prognosis. Monitoring CTC levels over time can help guide treatment decisions and assess treatment response [15].

Predictive Biomarkers:

Predictive biomarkers greatly influence the efficacy of particular medications or treatments. They enable medical professionals to tailor treatment programs to a patient's individual characteristics. Predictive biomarkers are often used in precision medicine to develop tailored

treatments and achieve better therapeutic outcomes. For example, HER2 status is a predictive biomarker for breast cancer. For HER2-positive patients, high HER2 expression indicates a favorable response to targeted therapy such as trastuzumab. Similarly, identifying specific gene mutations, such as EGFR in lung cancer, can help guide the selection of tyrosine kinase inhibitors, ultimately improving treatment outcomes [16].

Monitoring Biomarkers:

Healthcare professionals use monitoring biomarkers to track the progression of a disease or assess the effectiveness of treatment over time [18]. These biomarkers are essential for evaluating treatment efficacy and making necessary adjustments, if needed. For example, monitoring biomarkers help to measure kidney function and blood sugar levels in chronic conditions like diabetes, providing crucial information for holistic therapy [17].

In men with prostate cancer, prostate-specific antigen (PSA) is a useful biomarker for tracking the progression or burden of the disease. With the help of this personalized assessment, medical practitioners can assess the disease's progression and make informed decisions [18].

Healthcare professionals frequently measure symphysis fungal height throughout pregnancy. This procedure is a useful antenatal screening tool that enables the early identification of any fetal growth problems [20].

Safety Biomarkers:

Safety biomarkers are essential in clinical trials. They are used to evaluate the safety and tolerability of experimental medications or treatments. By identifying potential adverse effects or toxicities associated with the intervention, they help to safeguard the well-being of study participants. Additionally, safety biomarkers aid in evaluating the risk-benefit ratio of specific therapies [21].

Monitoring serum potassium levels can be a useful safety indicator when evaluating patients who are taking diuretics (which may lower levels), angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or aldosterone antagonists (which may cause hyperkalemia).

Proximity Biomarkers:

Proximity biomarkers indicate how closely a particular tissue or cell type is associated with a disease or condition. They pinpoint specific cell populations involved in the disease process [20]. These biomarkers are crucial for understanding disease causes and developing personalized treatments. For example, proximity biomarkers in neurodegenerative disorders enable us to identify the specific brain regions affected by the disease.

Imaging Biomarkers:

Imaging biomarkers play a crucial role in using various imaging techniques, such as MRI, PET, and CT scans. These techniques provide visualization and quantification of biological processes and structural changes within the body [19]. They provide useful information about how diseases develop, how treatments work, and how anatomical anomalies are formed. Imaging biomarkers are widely used in disciplines such as oncology, neurology, and cardiology and are very helpful in determining the risk of lung cancer. For example, the discovery of a straightforward lung lesion on an X-ray, CT scan, or MRI can lead to concerns about a neoplasm.

MODERN ADVANCEMENT OF BIOMARKERS:

The following key points are developed in biomarkers as modern advancements:

- Molecular-based medication development has made recent advancements.
- Biomarkers in drug expansion.
- The Drug discovery industry.
- Discovering Biomarkers Using Genomics.
- Aptasensors for Diabetes Biomarkers Using Electrochemistry.
- Immunosensors.
- Biomarkers of Alzheimer's Diagnosis.
- Blood Biomarkers of Amyloid Pathology.

Molecular-based medication development has made recent advancements:

Recent developments in clinical and basic research have made it possible to create "personalized" treatment plans [20]. Drugs with minimal toxicity or high tolerance have historically been used to treat cancer patients, regardless of whether they are effective for a particular patient, if their advantages have been demonstrated in both experimental and clinical settings [21]. Which kind of biomarker to utilize across the diverse range of illness processes. Because every cancer cell exhibits some level of genetic damage that may not be present in healthy body cells, genomic studies are important in the fight against cancer [22]. In physiological fluids such as blood, urine, cerebrospinal fluid, and secretions, proteins, peptides, and other metabolites are plentiful and easily accessible. These properties make them promising for

evaluating outcomes and researching changes in disease conditions [23].

Biomarkers in drug expansion:

Responding differently, being effective, and having risky side effects are the main obstacles in the development of cancer drugs. The drug industry, drug policy makers and administration [24]. To help with these issues, researchers are continually looking for pharmacogenomics and/or pharmacopoeia studies that could reveal useful molecular indicators. Colonic polyps may be the most closely related surrogates to colon cancer that have been employed as an endpoint for various clinical trials of calcium supplements, aspirin, and celecoxib. Biomarkers may be employed to improve drug discovery's effectiveness and caliber [25]. The hundreds of candidates that are normally screened during the drug development process can be evaluated in vitro using biomarkers. In Phase II clinical trials, biomarkers can also be employed to assess drug toxicity and pharmacokinetics. The majority of Phase II and Phase III trials use reduced death or disease-free survival as the primary endpoint, and studies are often lengthy [more than 10 years] and large (several thousand patients).

Drug discovery industry:

Disease understanding:

Usually, a disease cascade involves several steps. A biomarker may appear early or late in the cascade if it is directly connected to the pathophysiology of a disease. Upstream biomarkers are those that appear early in the pathophysiologic cascade [26]. Upstream biomarkers offer details on biological or physical interactions with the drug's molecular target. Downstream biomarkers are those that appear later in the pathophysiologic cascade. Suitable downstream biomarkers can forecast clinical benefits [27]. By giving more detailed knowledge about the mechanisms underlying therapeutic pathologies early in the discovery-development phase, a biomarker-based strategy has the potential to improve drug development pipeline quality. Second, it can increase process efficiency by complementing Techniques for discovering and minimizing attrition during medication development for unwanted compounds including genetic target identification and characterization.

Discovering Biomarkers Using Genomics:

Genetic biomarkers monitor changes in the quantity or makeup of DNA or RNA [28]. Examples of DNA-based biomarkers include copy number variation, mutations, and epigenetic alterations (including polymorphisms, somatic mutations, and other genetic variants). Long non-coding RNA (lncRNA), microRNA, and mRNA quantification are RNA expression-based biomarkers. Genes associated with the epithelial-mesenchymal transition, such as Zinc Finger E-box binding homeobox 2 (ZEB2), were found to have patterns of DNA methylation by Walter and colleagues and ERBB2, which can divide NSCLCs into two phenol-typically different subgroups of tumors with potential therapeutic value.

Aptasensors for Diabetes Biomarkers Using Electrochemistry:

Diabetes, commonly known as diabetes mellitus, is a chronic disease marked by chronically high blood sugar (hyperglycemia). Increased thirst, increased hunger, and frequent urination are some of the symptoms. However, untreated conditions might result in much more serious health issues. "Microvascular [retinopathy, nephropathy, neuropathy] and macrovascular [ischemic heart disease, stroke, peripheral vascular disease] endpoints" are the mabetes. Some of the symptoms include frequent urination, increased thirst, and increased appetite [30]. However, untreated conditions might result in much more serious health issues. "Microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (ischemic heart disease, stroke, peripheral vascular disease) endpoints" are the main consequences of diabetes. a superior biomarker and the industry standard for the ongoing checking of glucose levels. The very stable glycolated protein known as HbA1c is created in serum during the non-enzymatic interaction between the human hemoglobin (Hb) chains and N-terminal valine with glucose [31]. The time-averaged blood glucose level during a two- to three-month period is represented by the HbA1c level (%). An eye condition known as diabetic retinopathy (DR) is connected to diabetes. If undetected and mistreated, it can cause vision loss and blindness. Therefore, DR can be effectively prevented from causing serious permanent damage by early diagnosis and treatment. An important tear biomarker for DR is vascular endothelial growth factor (VEGF), and a high VEGF level is closely associated with DR. Several analytical methods, including capillary electrophoresis, immunoassays, boronate affinity chromatography, enzymatic tests, and several types of biosensors, have been used to identify the HbA1c level in human blood. Eissa, *et al*. (2017) developed a label-free

electrochemical aptasensor array for the assessment of total hemoglobin (tHb) and HbA1c in human whole blood [32].

Immunosensors:

Analytical biosensors known as "Immunosensors" use antibodies (Abs) to recognize antigens at the molecular level. These responses can be combined with effective physical transducers to produce highly selective chemical reactions [33]. Immunosensors have been extensively used in a variety of industries, including the assessment of food safety, environmental monitoring, and medical diagnosis, due to their distinctive selectivity, outstanding sensitivity, flexible applicability, and ease of handling [34]. They have proven particularly effective in the diagnosis of cancer, infections, and autoimmune, cardiovascular, and allergic illnesses.

Examples, the most common application for Norfloxacin (NOR) is the treatment of illnesses in animals. However, an excessive amount of NOR that remains in animal products like milk may disrupt the duplication of mammalian cells and lessen the effectiveness of antibiotics.

Zong, *et al*. developed a paper-based fluorescent immunoassay based on a QD-labeled NOR monoclonal antibody to detect NOR at the picogram level in milk [35]. Pre-immobilized NOR-BSA on paper could capture the QD-labeled antibodies, producing fluorescence. With higher NOR concentrations, the fluorescence intensity dropped. Additionally, this technology has the ability to simultaneously detect several antibiotics in various zones of the paper because antibodies that target various antibiotics can be labeled with various QDs that have various emission wavelengths.

Biomarkers of Alzheimer Diagnosis:

One of the indicators investigated in this potential COU is plasma total tau (T-tau) concentration. One study found that plasma tau was higher in the dementia stage of AD, even if the data were less apparent in the MCI stage of the disease [36]. According to a recent study by the Mayo Clinic Study of Aging, non-demented people who had greater plasma tau levels had impaired memory and less cortical thickness in an area that is characteristic of AD. There was significant overlap between eight groups in analyses comparing cognitive status, amyloidal, and neurodegenerative imaging indicators. The implication is that plasma tau may not be a helpful biomarker for diagnosing AD. Unfortunately, no clear correlation between plasma and CSF T-tau concentrations exists [37] and CSF and blood biomarkers usually have little to no association. In addition to the fact that almost all proteins have a variety of forms, the assay design may have an impact on the sample's equilibrium between bound and free analytes. Another biomarker generating a lot of interest is neuron-filament light. Recently, plasma sphingolipid changes in people with low body dementia [DLB], AD, and control participants were investigated. The researchers found significant variations in plasma ceramide and monohexosylceramide between dementia patients (AD and DLB) and controls, suggesting that these biomarkers may be useful in spotting possible pathologies associated with AD and/or DLB. O'Bryant and colleagues cross-validated a serum-based algorithm employing several platforms, animal models, and brain tissue in order to identify AD from controls. They also displayed preliminary outcomes regarding the algorithm's capacity to differentiate between PD and AD. Relative to screening tests, this study demonstrated higher positive and negative predictive values and established the locked-down referent population for a primary care AD blood screen. In the long run, it's likely true that the most practical and beneficial COU for blood-based biomarkers in the "diagnostic" domain will be to serve as the first stage of a multi-stage diagnostic process, with CSF and PET amyloid and tau imaging serving as the final diagnostics of the presence of AD pathology [38].

Blood Biomarkers of Amyloid Pathology:

Another COU with substantial potential to aid clinical trials is the discovery of blood-based biomarkers that can distinguish between patients with a high [or low] chance of becoming amyloid positive [39]. Recently, longitudinal plasma samples from people without dementia who had access to [11C] PiB PET scans were collected over a 12-year period and examined for proteomic markers. This study discovered seven plasma proteins, including A2M, Apo-A1, and many complement proteins, to be substantially linked with amyloid burden [40]. There is still more to be done before these discoveries are clinically useful [41]. It is essential to fully comprehend how other factors, such as pre-analytical factors, affect illnesses, diseases, and those associated therapies on the levels of these blood-based biomarkers, in addition to the requisite cross-validation and longitudinal knowledge. For instance, "hallmark" AD biomarkers have been shown to change in response to situations like depression, cardiac arrest, brain injury, and chemotherapy and hematological treatments [42]. This

Table 1. List of registered patents for biomarkers in the field of pharmaceuticals.

Sl. No.	Patent Number	Inventor Name	Publication Date	References
1	US-20230220483-A1	DUEÑAS PORTO; Marta Gloria Et Al.	2023-07-13	[43]
2	US-20230220478-A1	Howell; Michael D. Et Al.	2023-07-13	[44]
3	US-20230220401-A1	SIERKS; Michael Et Al.	2023-07-13	[45]
4	US-20230221318-A1	Hess; Nicholas Et Al.	2023-07-13	[47]
5	US-20230220485-A1	Davicioni; Elai Et Al.	2023-07-13	[48]
6	US-20230220479-A1	Pavel; Ana Brandusa Et Al.	2023-07-13	[49]
7	US-20230213521-A1	EL KHOURY; Victoria Et Al.	2023-07-06	[50]
8	US-20230213536-A1	Mcquiston; Beth Et Al.	2023-07-06	[51]
9	US-20230210455-A1	Deng; Sophie Xiaohui	2023-07-06	[52]
10	US-11693014-B2	Singbartl; Kai Et Al.	2023-07-04	[53]
11	US-20230204591-A1	Tlsty; Thea D. Et Al.	2023-06-29	[54]
12	US-20230204583-A1	Shroyer; Kenneth R. Et Al.	2023-06-29	[55]
13	US-20230204578-A1	Martin-Fernandez; Marisa Et Al.	2023-06-29	[56]
14	US-20230204592-A1	SHROYER; Kenneth Et Al.	2023-06-29	[57]
15	US-20230203583-A1	KHODAYARI; NAZLI Et Al.	2023-06-29	[58]
16	US-20230200716-A1	HERNANDEZ; Guillermo Horga Et Al.	2023-06-29	[59]
17	US-11686736-B2	Ballantyne; Christie Mitchell Et Al.	2023-06-27	[60]
18	US-11685953-B2	Avivar Valderas; Alvaro Et Al.	2023-06-27	[61]
19	US-11685954-B2	Liu; Xiaole Et Al.	2023-06-27	[62]
20	US-11692030-B2	Wallach; Todd Et Al.	2023-07-04	[63]
21	US-20230206300-A1	Lee; Ji Et Al.	2023-06-29	[64]
22	US-11685951-B2	Meng; Hui Et Al.	2023-06-27	[65]
23	US-11685952-B2	Choi; Jong Il	2023-06-27	[66]
24	US-11684617-B2	Neil; Garry A. Et Al.	2023-06-27	[67]
25	US-20230194551-A1	LEE; Choon-Hwan Et Al.	2023-06-22	[68]

process of moving from discovery to clinic should be carried out as a collaboration between academics and industry/biotech because that is the best method to take advantage of the various skill sets of those inside each organizational structure and to appropriately take into consideration the long-term plan and research plans [43]. Artificial intelligence (AI) aids the pharmaceutical corporations in preventing these kinds of losses during the medication development process and also enhances pharmaceutical research and development [46]. In the next section, the technique for advancing biomarker discovery through the stages of development into clinical deployment is revised.

RECENT ADVANCEMENT AND FUTURE PROSPECTIVE IN BIOMARKER:

In the future, a large number of advancements will be investigated, and some will be patented in the area of different biomarkers for the purpose of pharmaceuticals use. The various researches available in the field of biomarkers which are used in pharmaceuticals are listed in Table 1.

CONCLUSION:

Biomarkers have become indispensable tools in the pharmaceutical industry. They play a vital role in developing and optimizing innovative therapies by serving as measurable indicators of biological processes, disease states, or responses to treatment. Their existence provides essential insights into drug effectiveness, safety measures, and patient categorization.

Biomarkers play a crucial role in drug discovery, clinical trials, and personalized medicine. They serve multiple purposes such as identifying potential drug targets, evaluating the effectiveness of novel substances, and forecasting patient reactions to therapy. In clinical trials, biomarkers help in patient selection, disease progression monitoring, and therapeutic efficacy assessment. In the realm of personalized medicine, these biomarkers help identify patients who would benefit most from specific treatments and enable tailored therapies based on individual needs.

The successful integration of biomarkers in drug development pipelines has yielded numerous benefits. It not only improves the success rate of clinical trials but also allows for precision medicine approaches and expedites the translation of promising therapeutics from laboratory testing to bedside application. As biomarker research continues to evolve, it uses her new opportunities that hold immense potential for enhancing patient care.

The use of biomarkers is rapidly evolving in the pharmaceutical sector. Biomarkers are likely to be used in increasingly creative ways to improve patient care when new technologies are developed.

ACKNOWLEDGEMENT:

The author wishes to thank Ms. Suchita Wamankar, our professor-in-charge and Dr. Rajesh Kumar Nema, Principal of Rungta Institute of Pharmaceutical Science and Research, Bhilai, for their support and guidance in completing our project on the topic “The role of Biomarkers in the field of pharmaceuticals” and for carrying out this review work. It was a great learning experience.

REFERENCES:

1. LaBaer, Joshua. So, you want to look for biomarkers (introduction to the special biomarkers issue). J Proteome Res, 2005; 4: 1053-1059.
2. Perera, Frederica P, Weinstein IB. Molecular epidemiology: recent advances and future directions. Carcinogenesis, 2000; 21(3): 517-524.
3. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, *et al*. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Therap, 2001; 69(3): 89-95.
4. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 2006; 113(19): 2335-2362.
5. George P. Bring on the biomarkers. Nature, 2011; 469(7329): 156-157.
6. Joshua LB. So, you want to look for biomarkers (introduction to the special biomarkers issue). J Proteome Res, 2005; 4(4): 1053-1059.
7. Jeffrey C, Raynaud F, Jones L, Sugar R, and Dive C. Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Brit J Cancer, 2010; 103(9): 1313-1317.
8. Puntmann VO. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad Med J, 2009; 85(1008): 538-545.
9. Klepser S, Gabriella, Fountain S. Validation of Biochemical Biomarker Assays Used in Drug Discovery and Development: A review of challenges and solutions. In: Williams JA, Lalonde R, Koup JR, Christ DD, editors. Predictive Approaches in Drug Discovery and Development: Biomarkers and In Vitro/In Vivo Correlations. New York: Willey; 2012: pp. 23-48.
10. Flood DG, Marek GD, Williams M. Developing predictive CSF biomarkers - a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochem Pharmacol, 2011; 81(12): 1422-1434.
11. Paweletz CP., Jannik NA, Roy P, Kumiko N, Mansuo LH, Shangshuan UY, *et al*. Identification of direct target engagement biomarkers for kinase-targeted therapeutics. PLoS One, 2011; 6(10): e26459.
12. Naylor, Stephen. "Overview of biomarkers in disease, drug discovery and development." Drug Discovery; 2005: 21.
13. Sahu, Pradeep, Neha Pinkalwar, Ravindra Dhar Dubey, Shweta Paroha, Shilpi Chatterjee, and Tanushree Chatterjee. "Biomarkers: an emerging tool for diagnosis of a disease and drug development." Asian Journal of Research in Pharmaceutical Science; 2011, 1(1): 9-16.
14. Puntmann, V. O. "How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease." Postgraduate medical journal; 2009, 85(1008): 538-545.

15. Frank, Richard, and Richard Hargreaves. "Clinical biomarkers in drug discovery and development." Nature reviews Drug discovery; 2003, 2(7): 566-580..
16. Ferber, G. "Biomarkers and proof of concept." Methods and findings in experimental and clinical pharmacology; 2002, 24: 35-40.
17. Mayeux, Richard. "Biomarkers: potential uses and limitations." NeuroRx; 2004,1: 182-188.
18. Freedland, Stephen J., and Judd W. Moul. "Prostate specific antigen recurrence after definitive therapy." The Journal of urology; 2007, 177(6): 1985-1991.
19. Kessler, Larry G., Huiman X. Barnhart, Andrew J. Buckler, Kingshuk Roy Choudhury, Marina V. Kondratovich, Alicia Toledano, Alexander R. Guimaraes et al. "The emerging science of quantitative imaging biomarkers terminology and definitions for scientific studies and regulatory submissions." Statistical methods in medical research;2015 ,24(1): 9-26.
20. Lukas, Arno, Andreas Heinzel, and Bernd Mayer. "Biomarkers for capturing disease pathology as molecular process hyperstructure." BioRxiv; 2019: 573402.
21. Kaaks, R., E. Riboli, and R. Sinha. "Biochemical markers of dietary intake." IARC Scientific Publications; 1997, 142: 103-126.
22. Manne, Upender, Rashmi-Gopal Srivastava, and Sudhir Srivastava. "Keynote review: Recent advances in biomarkers for cancer diagnosis and treatment." Drug discovery today; 2005, 10(14): 965-976.
23. Kelloff, Gary J., Robert C. Bast Jr, Donald S. Coffey, Anthony V. D'Amico, Robert S. Kerbel, John W. Park, Raymond W. Ruddon et al. "Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue." Clinical cancer research;2004, 10(11): 3881-3884..
24. Wagner, John A. "Overview of biomarkers and surrogate endpoints in drug development." Disease markers; 2002, 18(2): 41-46.
25. Kelloff, Gary J., Richard L. Schilsky, David S. Alberts, Robert W. Day, Kathryn Z. Guyton, Homer L. Pearce, Jonathan C. Peck, Robert Phillips, and Caroline C. Sigman. "Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs." Clinical Cancer Research; 2004, 10,(11): 3908-3918..
26. Wagner, John A. "Overview of biomarkers and surrogate endpoints in drug development." Disease markers; 2002, 18(2): 41-46.
27. Li, Albert P. "Screening for human ADME/Tox drug properties in drug discovery." Drug discovery today; 2001, 6(7): 357-366..
28. Walter, Kim, Thomas Holcomb, Tom Januario, Pan Du, Marie Evangelista, Nithya Kartha, Leonardo Iniguez et al. "DNA methylation profiling defines clinically relevant biological subsets of non–small cell lung cancer." Clinical Cancer Research; 2012, 18(8): 2360-2373.
29. Forouhi, Nita Gandhi, and Nicholas J. Wareham. "Epidemiology of diabetes." Medicine; 2010, 38(11): 602-606.
30. Forbes, Josephine M., and Mark E. Cooper. "Mechanisms of diabetic complications." Physiological reviews; 2013, 93(1): 137-188.
31. Lin, Ying-Chin, Ching-Yu Lin, Hsiu-Mei Chen, Li-Pin Kuo, Cheng-En Hsieh, Xiang-He Wang, Chih-Wen Cheng, Chih-Yin Wu, and Yi-Su Chen. "Direct and label-free determination of human glycated hemoglobin levels using bacteriorhodopsin as the biosensor transducer." Sensors; 2020; 20 (24): 7274.
32. Mei, Chenyang, Luting Pan, Wenjin Xu, Hang Xu, Yuanyuan Zhang, Zhiying Li, Bin Dong et al. "An ultrasensitive reusable aptasensor for noninvasive diabetic retinopathy diagnosis target on tear biomarker." Sensors and ActuatorsB: Chemical;2021, 345: 130398.
33. Eissa, Shimaa, and Mohammed Zourob. "Aptamer-based label-free electrochemical biosensor array for the detection of total and glycated hemoglobin in human whole blood." Scientific reports; 2017, 7(1): 1016.
34. Sharma, Shikha, Ragini Raghav, Richard O'Kennedy, and Sudha Srivastava. "Advances in ovarian cancer diagnosis: A journey from immunoassays to immunosensors." Enzyme and Microbial Technology; 2016, 89: 15-30.
35. Li, Bingzhi, Anqi Xia, Shilin Zhang, Tiying Suo, Yujie Ma, He Huang, Xing Zhang, Yue Chen, and Xuemin Zhou. "A CRISPR-derived biosensor for the sensitive detection of transcription factors based on

the target-induced inhibition of Cas12a activation." Biosensors and Bioelectronics; 2021, 173: 112619.

36. Rosado, Miguel, Rafael Silva, Mariana G. Bexiga, John G. Jones, Bruno Manadas, and Sandra I. Anjo. "Advances in biomarker detection: Alternative approaches for blood-based biomarker detection." Advances in clinical chemistry; 2019, 92 : 141-199.
37. Olsson, Bob, Ronald Lautner, Ulf Andreasson, Annika Öhrfelt, Erik Portelius, Maria Bjerke, Mikko Hölttä et al. "CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis." The Lancet Neurology; 2016, 15(7): 673-684.
38. Dage, Jeffrey L., Alexandra MV Wennberg, David C. Airey, Clinton E. Hagen, David S. Knopman, Mary M. Machulda, Rosebud O. Roberts, Clifford R. Jack Jr, Ronald C. Petersen, and Michelle M. Mielke. "Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort." Alzheimer's & Dementia; 2016, 12(12): 1226-1234.
39. O'Bryant, Sid E., Guanghua Xiao, Fan Zhang, Melissa Edwards, Dwight C. German, Xiangling Yin, Tori Como et al. "Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues." Journal of Alzheimer's Disease; 2014, 42(4): 1325-1335.
40. Kaneko, Naoki, Akinori Nakamura, YukihikoWashimi, Takashi Kato, Takashi Sakurai, Yutaka Arahata, Masahiko Bundo et al. "Novel plasma biomarker surrogating cerebral amyloid deposition." Proceedings of the Japan Academy, Series B; 2014, 90(9): 353-364.
41. Swaminathan, Shanker, Shannon L. Risacher, Karmen K. Yoder, John D. West, Li Shen, Sungeun Kim, Mark Inlow et al. "Association of plasma and cortical amyloid beta is modulated by APOE ε4 status." Alzheimer's &Dementia ; 2014,10(1): e9-e18.
42. Van Gool, S. W., E. Van Kerschaver, P. Brock, Hans Pottel, F. Hulstaert, E. Vanmechelen, A. Uyttebroeck, A. Van De Voorde, and H. Vanderstichele. "Disease-and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies." Leukemia;2000, 14(12): 2076-2084.
43. Porto, Marta Gloria Dueñas, Cristian Suárez Cabrera, Jesús María Paramio González, And Félix Guerrero Ramos. "Biomarkers for predicting a patient's response to bcg therapy, methods and uses based thereon." U.S. Patent Application 17/907,315, filed July 13, 2023.
44. Chen, Qiyun, Zhiyun Ye, Sheng-Cai Lin, and Biaoyang Lin. "Recent patents and advances in genomic biomarker discovery for colorectal cancers." Recent Patents on DNA & Gene Sequences (Discontinued) ;2010,4(2): 86-93.
45. Neagu, Monica, Carolina Constantin, Cristiana Tanase, and Daniel Boda. "Patented biomarker panels in early detection of cancer." Recent patents on biomarkers; 2011, 1(1): 10-24.
46. Akhtar S*, Hussain S. An Artificial Intelligence in Formulation of Pharmaceutical Products. J Pharm Adv Res, 2020; 3(3): 811-817.
47. Nicholas, H. E. S. S., Christian Capitini, Kalyan Nadiminti, PeimanHematti, and Jenny Gumperz. "T cell specific biomarkers for predicting graft-vs-host disease and hematopoietic malignancy relapse following hematopoietic stem cell transplantation and treatment thereof." U.S. Patent Application 18/094,221, filed July 13, 2023.
48. DavicioniS, Elai, Nicholas George Erho, and Lucia Lam. "Cancer biomarkers and classifiers and uses thereof." U.S. Patent Application 17/929,881, filed July 13, 2023.
49. Pavel, Ana Brandusa, and Emma Guttman-yassky. "Biomarkers and classifier of psoriasis and methods of treatment." U.S. Patent Application 18/155,702, filed July 13, 2023..
50. Elkhoury; Victoria et al, Biomarkers For Detection Of Lung Cancer,US-20230213521-A1,July06,2023.
51. McQuiston, Beth, Saul Datwyler, and Raj Chandran. "Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan." U.S. Patent Application 18/147,094, filed July 6, 2023.
52. Deng, Sophie Xiaohui. "In vivo biomarkers of human limbal stem cell function." U.S. Patent Application 18/078,403, filed July 6, 2023.
53. Singbart; Kai et al, Biomarkersofrenal injury, US-11693014-B2, July04, 2023.

54. Tlsty; TheaD.et al, Cancer Biomarkers And Methods Of Use There Of, US-20230204591-A1, June29,2023.
55. Shroyer, Kenneth R., Luisa F. Escobar-hoyos, and Emily I. Chen. "Keratins as biomarkers for cervical cancer and survival." U.S. Patent Application 18/057,949, filed June 29,2023.
56. Martin-Fernandez, Marisa, David Clarke, Sarah Needham, Daniel Rolfe, and Michael Hirsch. "Receptor tyrosine kinase biomarkers." U.S. Patent 11,567,073, issued January 31, 2023.
57. SHROYER, Kenneth, M. O. Michelle, Annie SHROYER, and Luisa ESCOBAR-HOYOS. "Keratin 17 as a biomarker for head and neck cancers." U.S. Patent Application 18/051,551, filed June 29, 2023.
58. Khodayari; Nazli Et Al, Biomarkers For Assessing Liver Disease, US-20230203583-A1, June29, 2023.
59. Hernandez, Guillermo Horga, Clifford Mills Cassidy, and Kenneth Wengler. "Use of neuromelanin-sensitive mri as a biomarker of dopamine function." U.S. Patent Application 18/171,276, filed June 29, 2023.
60. Ballantyne; Christie Mitchell et al, Biomarkers to improve prediction of heart failure risk, US-11686736-B2, June 27, 2023.
61. AvivarValderas; Alvaro et al, Biomarkers and methods of treating cancer, US-11685953-B2, June 27, 2023.
62. Liu; Xiaole et al, Biomarkers predictive of endocrine resistance in breast cancer, US-11685954-B2, June 27, 2023.
63. Wallach; Todd et al, Biomarkers and methods for detection of seizures and epilepsy, US-11692030-B2, July 04, 2023.
64. Lee; Ji et al, Systems and Methods for Generating Personalized Skin Care Formulations Based on Biomarker Analysis, US-20230206300-A1, June 29, 2023.
65. Meng; Hui et al, Biomarkers for intracranial a neurysm, US-11685951-B2, June 27, 2023.
66. Choi; JongIl, Biomarker for predicting risk of recurrence in patients with paroxysmal atrial fibrillation, US-11685952-B2, June27, 2023.
67. Neil; Garry A.et al, Methods of diagnosing and treating ADHD in biomarker positive subjects, US-11684617-B2, June 27, 2023.
68. Lee ;Choon Hwan Et Al ,Biomarker In Blood Form Acular Edema And Use There Of,US-20230194551-A1,June 22,2023.

Conflict of Interest: None
Source of Funding: Nil
Paper Citation: Sahu B, Sahu B, Sahu J, Kumar D, Wamankar S*, Nema RK. The Role of Biomarkers in the Field of Pharmaceuticals. J Pharm Adv Res, 2023; 6(11): 1970-1979.